Leaf Expression Systems Launch First Line of Hypertrans® Research Products

Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins

29 May 2019: Norwich, UK Leaf Expression Systems, a contract development and manufacturing organisation specialising in the plant-based expression and production of proteins, vaccines, metabolites and complex natural proteins, has announced the launch of its online list of products available for purchase by researchers working within the life sciences and agricultural industries.

The products are produced in Nicotiana benthamiana using Hypertrans®, Leaf’s Agrobacterium-mediated transient expression technology. Hypertrans® is efficient, safe and simple to use to quickly produce proteins, vaccines, antibodies or enzymes in plants.

The products; Bet v 1-A – Betula verrucosa (European white birch) allergen 1-A, Cowpea Mosaic Virus VLPs, Horseradish Peroxidase (HRP) C1A, Human Nucleotide triphosphate diphosphatase NUDT15 (MTH2), MAb Anti-VEGF 165A, Phleum pratense (Common timothy) allergen 1 and Triosephosphate Isomerase (TPI) are all available for purchase for research purposes via its online platform.

Simon Saxby, CEO said ‘We are excited to launch our first proprietary products produced in plants using Hypertrans®. We will continue to add products that are difficult or uneconomical to produce using other expression systems to add to the research tools available to the life science community and which also demonstrate the extreme flexibility and capability of Hypertrans® for the rapid manufacture of a wide range of biologics on commercially viable scales’.

END

Contact:

Media

Richard Hayhurst Associates
Richard Hayhurst
Richard@richardhayhurstassociates.com

Leaf Expression Systems
Polly Ferris
Marketing and Communications Officer
Leaf Expression Systems
ferrisp@leafexpressionsystems.com
01603 859298

 

About Leaf Expression Systems

Leaf Expression Systems is a contract development and manufacturing business specialising in plant-based expression and production of proteins, vaccines and complex natural products for research and commercial applications.  It uses Hypertrans®, the proprietary transient expression technology.

The Hypertrans® system allows for the rapid simultaneous production of multiple gene products in a controlled and coordinated manner within the tissues of plants.  Using gene synthesis and modular vectors, new products such as vaccines, antibodies or enzymes can be produced at speed and on a large scale, so it is well suited to be able to rapidly respond to emergencies like pandemics.

Leaf Expression Systems is based in a purpose-built, state-of-the-art facility on Norwich Research Park, that boasts of four environmentally controlled growing rooms, plant potting areas, a plant inoculation area, microbiology/molecular biology labs, protein purification and natural product processing facilities.

 

leafexpressionsystems.com

Plant Bioscience Ltd transfers control of Hypertrans® plant-based biologics and vaccines expression technology to Leaf Expression Systems Ltd

14 May 2019: Norwich Plant Bioscience Ltd (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business. Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans® technology and associated patented intellectual property. This extension of Leaf’s rights will ensure that Leaf’s clients are able to use Hypertrans® for the manufacture of their products in multiple geographical locations to meet the needs of individual markets and to enable clients to take advantage of lower manufacturing costs in some of these markets.

Leaf’s CEO Simon Saxby commented “I am delighted that we have strengthened our relationship with PBL and that we can now offer our clients the assurances they need in order to plan for scale up manufacture using Hypertrans® in the locations that are most appropriate for the target indications of their new biologic drugs or vaccines”.
PBL’s Managing Director Dr Jan Chojecki added “Leaf has been outstandingly successful in establishing its technical operations and developing its customer base and partnering activity. Now is the time to put Leaf fully in the driving seat with regard to this important and proprietary intellectual property asset developed originally by Professor George Lomonossoff at the John Innes Centre”.
Ends

For further information, contact:
Polly Ferris, Marketing & Communications Officer.
E: ferrisp@leafexpressionsystems.com
T: 01603 859 298

Notes to editors:

About Leaf Expression Systems

Leaf Expression Systems is a contract development and manufacturing business specialising in plant-based expression and production of proteins, vaccines and complex natural products for research and commercial applications. It uses Hypertrans®, the proprietary transient expression technology, which was originally developed by Professor George Lomonossoff of the John Innes Centre.

The Hypertrans® system allows for the rapid simultaneous production of multiple gene products in a controlled and coordinated manner within the tissues of plants. Using gene synthesis and modular vectors, new products such as vaccines, antibodies or enzymes can be produced at speed and on a large scale, so it is well suited to be able to rapidly respond to emergencies like pandemics.

Leaf Expression Systems is based in a purpose-built, state-of-the-art facility on Norwich Research Park, that boasts of four environmentally controlled growing rooms, plant potting areas, a plant inoculation area, microbiology/molecular biology labs, protein purification and natural product processing facilities.

leafexpressionsystems.com

About PBL
PBL (www.pbltechnology.com) is the intellectual property management and technology commercialization company of the John Innes Centre and others.

For further information please go to:
www.leafexpressionsystems.com and twitter.com/leaf_expression

CEO Update from Simon Saxby

Since our last update in October 2018, I am delighted to report that a lot has happened at Leaf in just a few short months. We have added some new members to the team to strengthen our depth and capability, we have secured a number of commercial contracts and collaborations with both pharma and biotech companies, and in January this year Richard Hart joined us as Business Development Director to lead the growth of our contract development and manufacturing services business.

As a big supporter of apprenticeship programmes, I am also pleased to report that our two apprentices are about to “graduate” and complete their apprenticeships. Both Joe and Karen have demonstrated the value of combining college-based learning with on the job training, and we are delighted that they are staying with us as valued members of the team.

The global CDMO market is forecast for further significant growth, with some estimates predicting that the global value of outsourcing will grow to over $87.6 billion by 2027. The fact that manufacturing biologics in plants is finally emerging as a genuine commercially viable option for reducing the time to market and the cost of drugs and vaccines to patients means that with our Hypertrans® transient plant expression technology, Leaf is perfectly placed to take a leading role in helping to deliver new and better drugs, free from animal derived products, that will lead to improved patient outcomes in the future.

We are also excited to announce the launch of our Products Page on the Leaf website! The team have produced a number of products that exemplify the production capability of Hypertrans® in terms of yield and functionality, and the products themselves are valuable research reagents which we are making available through our website. Our ‘first wave’ of products include an antibody, and enzyme, a virus-like particle and an allergen – all of which can be found here. We will be expanding the range of products that are available, including products that are difficult to express in mammalian or microbial systems, but which do express well and more cost effectively with Hypertrans® in plants. These will include cytokines, growth factors etc that are absolutely necessary for the manufacture of advanced therapies but are also extremely expensive to produce using current methods.

And last, but certainly not least, we were proud to be selected as a Finalist in the “Excellence in Life Sciences” category in the South Norfolk Business Awards 2019.

These are exciting times for Leaf and we are looking forward to tackling the challenges that we, and everyone else in the industry face, in improving the quality of life of people around the World.

Best,

Simon.

Press Release: Leaf Expression Systems Appoints Richard Hart as Business Development Director 

21st January 2019

Press Release: Leaf Expression Systems Appoints Richard Hart as Business Development Director 

Norwich, UK: Leaf Expression Systems, a contract biopharmaceutical development business rapidly emerging as the leader in the exciting new area of plant-based expression of proteins, metabolites and complex natural products, announced today that Richard Hart has joined the company as Business Development Director. With over thirty years of experience in the biopharma sector, Richard will play a major role in ensuring Leaf realises the full value of its game-changing plant transient expression technology, Hypertrans®, through establishing commercial collaborations in key markets and own pipeline development.

Richard has particularly strong knowledge of the biologics field, ranging from his most recent position as Global Business Development Director at Stelis Biopharma, through similar senior management roles at Syngene, Stratophase, Baxter Healthcare, Fujifilm Diosynth Biologics and CMC Biologics.

Leaf Expression Systems CEO, Simon Saxby, commented: “I am delighted to welcome Richard to the Leaf Expression Systems team at such an important time in the growth of the business. I have worked with him in the past and am certain that his skillset and experience will be invaluable as we aim to establish Leaf Expression Systems as a partner of choice by adding real value to the research and development programmes of our clients across the globe.”

Richard Hart added: “Having been heavily involved in the biologics sector throughout my career, I immediately saw the potential of Leaf. By providing an innovative way of rapidly and cost effectively producing proteins, vaccines and complex biomolecules, their Hypertrans® technology offers a much-needed solution to the significant financial pressures currently being experienced by the global life sciences industry. The new multimillion facility provides a strong base to deliver the company’s vision and I look forward to working with the excellent team here.”

Ends 

For further information, contact:
Farhan Mitha, Marketing & Communications Officer.
E: Mithaf@leafexpressionsystems.com
T: 01603 859 298

Notes to editors:

About Leaf Expression Systems
Leaf Expression Systems is a new contract development business specialising in the plant-based expression and production of proteins, metabolites and complex natural products for research and biomedical applications using a proprietary, transient expression technology, Hypertrans®.

For further information please go to:
www.leafexpressionsystems.com and twitter.com/leaf_expression